Philip Morris (PM) Offering Possible 12.02% Return Over the Next 21 Calendar Days

Philip Morris's most recent trend suggests a bullish bias. One trading opportunity on Philip Morris is a Bull Put Spread using a strike $84.50 short put and a strike $79.00 long put offers a potential 12.02% return on risk over the next 21 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $84.50 by expiration. The full premium credit of $0.59 would be kept by the premium seller. The risk of $4.91 would be incurred if the stock dropped below the $79.00 long put strike price.

The 5-day moving average is moving up which suggests that the short-term momentum for Philip Morris is bullish and the probability of a rise in share price is higher if the stock starts trending.

The 20-day moving average is moving up which suggests that the medium-term momentum for Philip Morris is bullish.

The RSI indicator is at 63.69 level which suggests that the stock is neither overbought nor oversold at this time.

To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here


LATEST NEWS for Philip Morris

Tobacco campaign group looks to name and shame
Thu, 25 Jul 2019 04:15:27 +0000
An online platform naming companies that help to promote the tobacco industry is the latest effort from a $20m initiative funded by the US billionaire Michael Bloomberg to counter tobacco industry tactics. The online database, launched on Thursday, was compiled by Stopping Tobacco Organisations and Products, the first globally co-ordinated tobacco industry campaign group. It lists companies, think tanks and other organisations that Stop believes promote the tobacco industry without necessarily acknowledging their links to the sector, according to the researchers.

Philip Morris' Earnings Release Puts Spotlight on Staple ETFs
Wed, 24 Jul 2019 22:44:10 +0000
We study the impact of Philip Morris' (PM) Q2 earnings release on ETFs with exposure to the stock.

Around $35, Tilray Stock Is a Buy
Wed, 24 Jul 2019 19:00:12 +0000
It's hard to believe, but the 52-week high for Tilray (NASDAQ:TLRY) is $300. TLRY reached its nose-bleed valuation last October. Except for a couple of rallies, it's been downhill ever since.Source: Shutterstock InvestorPlace – Stock Market News, Stock Advice & Trading TipsTrading around $42 as I write this, I still wouldn't buy it. However, if Tilray stock were to fall into the mid-$30s, I'd probably change my tune. Here's why. The Latest Tilray NewsFor Tilray stock to move higher, like any other investment, it's got to provide investors with a catalyst or two. The last catalyst TLRY provided was the June 10 announcement that it had extended the lock-up period for up to two years on 77% of its total outstanding shares. By providing an orderly release of 75 million TLRY shares, formerly held by Privateer Holdings, Tilray's minority shareholders can breathe a sigh of relief that the market won't be flooded with company stock.Between June 10 and June 21, TLRY stock moved 17% higher on the news — to $50.45 — only to fall back into the low $40s in July on the lack of a catalyst. As I look around for a nugget of information that might excite investors, the only thing I can come up with is the appointment of five executives for the company's European operations on July 5. * 10 Small-Cap, Up-And-Coming Stocks to Keep on Your Radar "Having strong people on our team is critical to our success and growth," said Sascha Mielcarek, Tilray's managing director of Europe, about the five executives hired. "We're thrilled to welcome this group of highly skilled leaders to our team. Arne, Jose, Maike, Nadja and Natalie all join Tilray with wide-ranging experience in regulated industries. We're confident their appointments will accelerate our global growth strategy and help strengthen our position in Europe and other international markets." Portugal will serve as the company's hub of operations in Europe. In April, the company launched its $20 million, 250,000-square-foot facility in Cantanhede, Portugal. As part of the ribbon-cutting ceremony, the company showed off its new facility to local government officials and Canadian healthcare professionals. The tour came on the heels of a successful indoor harvest at the facility. It now plans to hire 200 employees for the facility, which produces pharmaceutical-grade medical cannabis. Portugal looks to become one of the leaders in the European medical market, which is expected to hit $65.6 billion by 2028.Although Italy and Germany are easily the two largest medical markets in Europe, Portugal is likely to punch above its weight as the European cannabis industry continues to mature. Having several executives in place who understand the regulatory nature of cannabis will be helpful as Tilray stakes out its piece of the global marketplace. It's not news that Philip Morris (NYSE:PM) is investing in Tilray, but it is crucial to the company's development in Europe. The Company's Cultivation RecordI'm not as concerned about how much cannabis Tileay produces as I am about the kinds of products it's got in the development pipeline. As I said in June, the company's purchase of Manitoba Harvest for $316 million, wasn't a flashy deal, but it got Tilray into the CBD-infused foods market in North America, which is going to be huge. It's the quality of Tilray's partnerships that matter, not necessarily the cultivation numbers at the present moment. Having a research partnership with Anheuser-Busch (NYSE:BUD) that could lead to the production of cannabis-infused beverages is more important at this point than the total number of kilograms of cannabis it's sold to date.My InvestorPlace colleague Luke Lango recently pointed out that Tilray sold only 3,000 kilograms of cannabis in the latest quarter, one-third the amount of both Canopy Growth (NYSE:CGC) and Aurora Cannabis (NYSE:ACB). While that's true, I still believe that the dry flower isn't going to be the major winner in a global cannabis industry; the winners are going to be edibles and cannabis-infused beverages with the dry flower commoditized to a certain extent. Maybe I'll be proven wrong, but I don't think so. Lagging behind Canopy and Aurora isn't the death knell for Tilray. The Bottom Line on TLRY StockAs we've moved further into 2019, I've become more positive about Tilray's chances of becoming a global player in the cannabis space. I wouldn't have said that a year ago. As a CEO, Brendan Kennedy seems far more focused on the bigger picture while remaining patient about the speed at which Tilray grows. That's fantastic news if you own Tilray stock. * 7 Stocks to Sell This Summer Earnings Season However, I still feel as though Tilray hasn't earned enough street cred to be valued higher than Canopy or Aurora based on price-to-sales, price-to-book, or some other metric that's an apples-to-apples comparison. If it drops to $35, I'll change my tune.At the time of this writing Will Ashworth did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 5G Stocks to Connect Your Portfolio To * 7 Stocks to Sell This Summer Earnings Season * 6 Upcoming IPOs for July The post Around $35, Tilray Stock Is a Buy appeared first on InvestorPlace.

Swiss minister under fire for tobacco sponsorship of Expo pavilion
Wed, 24 Jul 2019 18:03:58 +0000
Swiss Foreign Minister Ignazio Cassis is under fire over a 1.8 million Swiss francs ($1.8 million) sponsoring deal his department struck with tobacco giant Philip Morris International to help fund Switzerland's Expo 2020 pavilion in Dubai. The World Health Organization (WHO) is scrutinising the pact, while the Swiss School of Public Health, a group of eight universities offering health education, told Cassis in a letter made public on Wednesday that taking tobacco money contradicts ethical principles of the health sciences.

UPDATE 1-Swiss minister under fire for tobacco sponsorship of Expo pavilion
Wed, 24 Jul 2019 18:01:28 +0000
Swiss Foreign Minister Ignazio Cassis is under fire over a 1.8 million Swiss francs ($1.8 million) sponsoring deal his department struck with tobacco giant Philip Morris International to help fund Switzerland's Expo 2020 pavilion in Dubai. The World Health Organization (WHO) is scrutinising the pact, while the Swiss School of Public Health, a group of eight universities offering health education, told Cassis in a letter made public on Wednesday that taking tobacco money contradicts ethical principles of the health sciences.

Be Sociable, Share!

Related Posts

 

MarketTamer is not an investment advisor and is not registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory Authority. Further, owners, employees, agents or representatives of MarketTamer are not acting as investment advisors and might not be registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory.


This company makes no representations or warranties concerning the products, practices or procedures of any company or entity mentioned or recommended in this email, and makes no representations or warranties concerning said company or entity’s compliance with applicable laws and regulations, including, but not limited to, regulations promulgated by the SEC or the CFTC. The sender of this email may receive a portion of the proceeds from the sale of any products or services offered by a company or entity mentioned or recommended in this email. The recipient of this email assumes responsibility for conducting its own due diligence on the aforementioned company or entity and assumes full responsibility, and releases the sender from liability, for any purchase or order made from any company or entity mentioned or recommended in this email.


The content on any of MarketTamer websites, products or communication is for educational purposes only. Nothing in its products, services, or communications shall be construed as a solicitation and/or recommendation to buy or sell a security. Trading stocks, options and other securities involves risk. The risk of loss in trading securities can be substantial. The risk involved with trading stocks, options and other securities is not suitable for all investors. Prior to buying or selling an option, an investor must evaluate his/her own personal financial situation and consider all relevant risk factors. See: Characteristics and Risks of Standardized Options. The www.MarketTamer.com educational training program and software services are provided to improve financial understanding.


The information presented in this site is not intended to be used as the sole basis of any investment decisions, nor should it be construed as advice designed to meet the investment needs of any particular investor. Nothing in our research constitutes legal, accounting or tax advice or individually tailored investment advice. Our research is prepared for general circulation and has been prepared without regard to the individual financial circumstances and objectives of persons who receive or obtain access to it. Our research is based on sources that we believe to be reliable. However, we do not make any representation or warranty, expressed or implied, as to the accuracy of our research, the completeness, or correctness or make any guarantee or other promise as to any results that may be obtained from using our research. To the maximum extent permitted by law, neither we, any of our affiliates, nor any other person, shall have any liability whatsoever to any person for any loss or expense, whether direct, indirect, consequential, incidental or otherwise, arising from or relating in any way to any use of or reliance on our research or the information contained therein. Some discussions contain forward looking statements which are based on current expectations and differences can be expected. All of our research, including the estimates, opinions and information contained therein, reflects our judgment as of the publication or other dissemination date of the research and is subject to change without notice. Further, we expressly disclaim any responsibility to update such research. Investing involves substantial risk. Past performance is not a guarantee of future results, and a loss of original capital may occur. No one receiving or accessing our research should make any investment decision without first consulting his or her own personal financial advisor and conducting his or her own research and due diligence, including carefully reviewing any applicable prospectuses, press releases, reports and other public filings of the issuer of any securities being considered. None of the information presented should be construed as an offer to sell or buy any particular security. As always, use your best judgment when investing.